Cyclin D1 / bcl-1 Ab-1 (Clone DCS-6)
Mouse Monoclonal Antibody
Cat. #MS-210-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Purified Ab with BSA and Azide)
Cat. #MS-210-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)
Cat. #MS-210-B0, -B1, or -B (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Biotin-Labeled Ab with BSA and Azide)
Cat. #MS-210-PCL (0.1ml) (Positive Control for Western Blot)

Description: Cyclin D1 or PRAD-1 or bcl-1 is one of the key cell cycle regulators, is a putative proto-oncogene overexpressed in a wide variety of human neoplasms including mantle cell lymphomas (MCL)

Comments: Ab-1 is highly specific to cyclin D1. It neutralizes the activity of cyclin D1 in vivo.

Mol. Wt. of Antigen: 36kDa

Epitope: Not determined

Species Reactivity: Human, Monkey, Mouse, Rat, and Dog.

Clone Designation: DCS-6

Ig Isotype / Light Chain: IgG2a / κ

Immunogen: Human recombinant full length cyclin D1 protein

Applications and Suggested Dilutions:
• Biological Blockade (Order Ab without azide)
• Flow Cytometry
• Immunofluorescence
• Immunoprecipitation (Co-precipitates Cdk4) (Native and denatured) (Use Protein A) (Ab at 2µg/mg protein lysate)
• Western Blotting (Ab 1-2µg/ml for 2hrs at RT)
• Immunohistology (Not Suitable; Use Cyclin D1 Clone SP4)

The optimal dilution for a specific application should be determined by the investigator.

Cellular Localization: Nuclear

Positive Control: MAD109 cells. Mantle cell lymphomas and breast carcinoma.

Supplied As: 200µg/ml Ab purified from ascites fluid by Protein A chromatography. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide. Also available without BSA and azide at 1mg/ml, or Prediluted antibody which is ready-to-use for staining of formalin-fixed, paraffin-embedded tissues.

Storage and Stability:
Ab with sodium azide is stable for 24 months when stored at 2-8°C. Antibody WITHOUT sodium azide is stable for 36 months when stored at below 0°C.

Key References:

Limitations and Warranty:
Our products are intended FOR RESEARCH USE ONLY and are not approved for clinical diagnosis, drug use or therapeutic procedures. No products are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our data sheets and website. Our warranty is limited to the actual price paid for the product. NeoMarkers is not liable for any property damage, personal injury, time or effort or economic loss caused by our products.

Material Safety Data:
This product is not licensed or approved for administration to humans or to animals other than the experimental animals. Standard Laboratory Practices should be followed when handling this material. The chemical, physical, and toxicological properties of this material have not been thoroughly investigated. Appropriate measures should be taken to avoid skin and eye contact, inhalation, and ingestion. The material contains 0.09% sodium azide as a preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material as indicated above. The National Institute of Occupational Safety and Health has issued a bulletin citing the potential explosion hazard due to the reaction of sodium azide with copper, lead, brass, or solder in the plumbing systems. Sodium azide forms hydrazoic acid in acidic conditions and should be discarded in a large volume of running water to avoid deposits forming in metal drainage pipes.

For Research Use Only
Cyclin D1 / bcl-1 Ab-1 (Clone DCS-6)
Mouse Monoclonal Antibody
Cat. #MS-210-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Purified Ab with BSA and Azide)
Cat. #MS-210-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)
Cat. #MS-210-B0, -B1, or -B (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Biotin-Labeled Ab with BSA and Azide)
Cat. #MS-210-PCL (0.1ml) (Positive Control for Western Blot)

Additional KeyReferences:
4. Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol and Cell Biol, 1995, 15:2600-11.
5. Lukas J; Bartkova J; Welcker M; Petersen OW; Peters G; Strauss M; Bartek J. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene, 1995, 10:2125-34.
11. Lukas J; Jadayel D; Bartkova J; Nacheva E; Dyer MJ; Strauss M; Bartek J. BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene, 1994, 9(8):2159-67.
12. Lukas J; Muller H; Bartkova J; Spitzkovsky D; Kjerulf AA; Jansen-Durr P; Strauss M; Bartek J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell’s requirement for cyclin D1 function in G1. Journal of Cell Biology, 1994, 125(3):625-38.
13. Lukas J; Pagano M; Staskova Z; Draetta G; Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene, 1994, 9(3):707-18.
14. Muller H; Lukas J; Schneider A; Warthoe P; Bartek J; Eilers M; Strauss M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(8):2945-9.